"Samchundang Pharmaceutical Chairman Becomes One of Korea's Top 10 Wealthiest Despite Stock Halving to 500,000 Won... What Happened?"

Yoon Daein Ranked 10th Among Korea’s Wealthiest by Forbes
Total Assets Estimated at USD 5.9 Billion Based on March 27 Closing Price and Exchange Rate
Surpasses Park Hyeon-joo of Mirae Asset and Bom Kim of Coupang

Yoon Daein, Chairman of Samchundang Pharmaceutical, who recently saw the company’s stock price plummet from over 1 million won per share—earning it the nickname "Emperor Stock"—to the 500,000 won range within a week amid contract-related controversy, has made it into Korea’s top 10 wealthiest individuals. Ironically, this highlights the negative aspect of the bio sector, where valuations are driven more by future narratives than by current profits.

Samchundang Pharmaceutical Headquarters. Samchundang Pharmaceutical.

According to the financial investment industry on April 15, Chairman Yoon Daein was recently ranked 10th on the list of Korea’s wealthiest individuals published by the U.S. business magazine Forbes. His total assets were estimated at 5.9 billion dollars. He surpassed Mirae Asset Group Chairman Park Hyun Joo (12th, 4.9 billion dollars), Kakao founder Kim Beomsoo (13th, 3.8 billion dollars), and Bom Kim (Kim Beomseok), Chairman of the Board at Coupang (14th, 3.2 billion dollars). The head of a company whose stock price plunged due to controversy over the overvaluation of a generic oral obesity and diabetes drug contract has now entered the very top tier of the rich list.

Forbes assessed assets based on the market closing price and the KRW-USD exchange rate as of March 27. This figure is not adjusted for the intrinsic value of the business or readily liquid assets, but rather reflects the market capitalization of listed shares at that point in time.

At that time, Samchundang Pharmaceutical’s stock price closed at 1.11 million won, a figure already reflecting a mix of extreme expectations and controversy. In the company’s regulatory filing on February 26 regarding a European contract, the confirmed payment was stated as 30 million euros (about 50.8 billion won). However, a press release issued the same day described the deal as being worth 5.3 trillion won, leading to accusations of exaggeration. On March 30, the company announced a contract for oral semaglutide in the U.S., securing about 100 million dollars in milestone payments and promoting it as an "exclusive" deal. However, the term "exclusive" was omitted from the official disclosure, fueling further market confusion. On March 31, the Korea Exchange issued a preliminary designation notice for Samchundang Pharmaceutical as an unfaithful disclosure company due to failure to make a fair disclosure regarding business performance outlook. Subsequently, the company’s refusal to disclose the identity of counterparties and suspicions of stock price manipulation caused the stock to plunge further.

Ultimately, Chairman Yoon’s entry into Korea’s top 10 wealthiest individuals is seen as evidence of how quickly Korean bio stocks can be revalued based on expectations and narratives. Ordinary investors have difficulty independently verifying complex technology, patent, and licensing contracts, making stock prices highly sensitive to press releases, analyst comments, and keywords that fuel expectations. As the Samchundang Pharmaceutical controversy grew, distrust spread beyond individual stocks to the broader bio sector, causing many stocks to plunge and the KRX Healthcare Index to drop by as much as 5.98% in a single day.

Jeon Inseok, CEO of Samchundang Pharm, is attending a press conference held at the Samchundang Pharm headquarters in Seocho-gu, Seoul on the 6th. Photo by Yonhap News

An industry insider stated, "It is excessive to generalize that all Korean bio stocks are in a bubble based solely on the Samchundang Pharmaceutical case. However, this incident concisely demonstrates the vulnerability of the Korean bio sector, where technology value is often evaluated ahead of actual performance, making it easy for any premium to quickly collapse into a bubble controversy if disclosure reliability and information transparency break down."

This content was produced with the assistance of AI translation services.